Curcumin (a constituent of turmeric): New treatment option against COVID-19.
Curcumin (a constituent of turmeric): New treatment option against COVID-19.
复制标题
姜黄素（姜黄的组成部分）：针对Covid-19的新治疗选择。
DOI：
10.1002/fsn3.1858
复制
发表时间：
2020-10
影响因子：
3.9
通讯作者：
Hosseinzadeh H
中科院分区：
文献类型：
--
作者：
Babaei F;Nassiri-Asl M;Hosseinzadeh H
2019年12月下旬，呼吸道疾病暴发疫情在武汉、中国等地出现，并在全球范围内蔓延。世界卫生组织(WHO)将该病命名为严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)，由一种新的贝塔冠状病毒成员引起。几种药物被开给患者，一些临床试验正在进行中。科学家们正在努力寻找一种针对这种病毒的特效药。本文就冠状病毒病2019年(新冠肺炎)的发病机制、临床特点和目前的治疗方法进行综述。然后，我们介绍了姜黄素可能的治疗作用及其抗冠状病毒19的分子机制。姜黄素作为姜黄的有效成分，已经进行了多项实验和临床试验研究。姜黄素具有抗病毒、抗伤害性、抗炎、解热和抗疲劳等作用，可以有效地控制新冠肺炎感染者的症状。它具有多种分子机制，包括抗氧化、抗细胞凋亡和抗纤维化特性，对Toll样受体、核因子-κB、炎性细胞因子和趋化因子以及缓激肽具有抑制作用。科学证据表明，姜黄素可能对新冠肺炎有潜在的治疗作用。因此，应该考虑将姜黄素用于临床试验，作为一种新的治疗方案。姜黄素具有抗伤害性、解热、抗疲劳、止吐等作用。姜黄素可减轻新冠肺炎感染者的症状，通过抑制TLRMAPK/NF-κB信号通路减少炎性细胞因子的产生。姜黄素可能通过抗炎作用减轻ARDS和肺纤维化。
In late December 2019, the outbreak of respiratory illness emerged in Wuhan, China, and spreads worldwide. World Health Organization (WHO) named this disease severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) caused by a new member of beta coronaviruses. Several medications are prescribed to patients, and some clinical trials are underway. Scientists are trying to find a specific drug against this virus. In this review, we summarize the pathogenesis, clinical features, and current treatments of coronavirus disease 2019 (COVID‐19). Then, we describe the possible therapeutic effects of curcumin and its molecular mechanism against coronavirus‐19. Curcumin, as an active constituent of Curcuma longa (turmeric), has been studied in several experimental and clinical trial studies. Curcumin has some useful clinical effects such as antiviral, antinociceptive, anti‐inflammatory, antipyretic, and antifatigue effects that could be effective to manage the symptoms of the infected patient with COVID‐19. It has several molecular mechanisms including antioxidant, antiapoptotic, and antifibrotic properties with inhibitory effects on Toll‐like receptors, NF‐κB, inflammatory cytokines and chemokines, and bradykinin. Scientific evidence suggests that curcumin could have a potential role to treat COVID‐19. Thus, the use of curcumin in the clinical trial, as a new treatment option, should be considered. Curcumin has antinociceptive, antipyretic, antifatigue, and antiemetic effects. Curcumin could alleviate symptoms of the infected patient with COVID‐19. Curcumin could reduce inflammatory cytokines via inhibiting TLR/MAPK/NF‐κB signaling. Curcumin might attenuate ARDS and pulmonary fibrosis due to anti‐inflammatory properties.
登录
查看更多内容
DOI：
10.1124/jpet.110.171876
发表时间：
2010-12-01
影响因子：
3.5
作者：
Broadley, Kenneth J.;Blair, Alan E.;Ford, William R.
通讯作者：
Ford, William R.
影响因子：
168.9
作者：
Chan, Jasper Fuk-Woo;Yuan, Shuofeng;Yuen, Kwok-Yung
通讯作者：
Yuen, Kwok-Yung
影响因子：
120.7
作者：
Fowler, Alpha A., III;Truwit, Jonathon D.;Halquist, Matthew
通讯作者：
Halquist, Matthew
DOI：
10.12659/msm.908714
发表时间：
2018-02-26
期刊：
Medical science monitor : international medical journal of experimental and clinical research
影响因子：
--
作者：
Cheng K;Yang A;Hu X;Zhu D;Liu K
通讯作者：
Liu K
影响因子：
3.7
作者：
Ferreira VH;Nazli A;Dizzell SE;Mueller K;Kaushic C
通讯作者：
Kaushic C